Glukoza Hztm (Glucose, Anhydrous)

Glukoza Hztm is an intravenous solution for injection containing glucose, anhydrous as the sole active ingredient. It is supplied in an unspecified strength and is marketed within the European Union. As an excipient classified under parenteral nutrition, Glukoza Hztm provides an immediate source of glucose for cellular metabolism when administered intravenously. The product is used under medical supervision for specific metabolic and nutritional indications in clinical practice.

Glukoza Hztm is indicated for situations where rapid glucose supplementation is required.

- Treatment of acute hypoglycemia in patients unable to take oral glucose. - Energy supplementation during short‑term fasting or pre‑operative preparation. - Component of total parenteral nutrition regimens for patients unable to receive enteral feeding. - Support for metabolic needs during critical illness or severe trauma. - Adjunct in electrolyte‑balanced solutions for intravenous therapy.

When administered intravenously, Glukoza Hztm may be associated with a range of observed effects.

Common: - Transient hyperglycemia. - Mild nausea or vomiting. - Local irritation at the injection site. - Temporary electrolyte shifts, particularly potassium.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Hypersensitivity reactions such as rash, itching, or anaphylaxis. - Fluid overload in patients with compromised cardiac function. - Hyperosmolar coma in extreme cases.

Safe use of Glukoza Hztm requires attention to patient condition and clinical context.

- Assess blood glucose levels before and during infusion. - Adjust dose in patients with renal or hepatic impairment. - Monitor for signs of fluid overload, especially in heart failure. - Use caution in diabetic patients to avoid excessive glucose spikes. - Avoid rapid infusion rates that may cause osmotic shifts. - Ensure compatible IV fluids; incompatibility may cause precipitation. - Discontinue if hypersensitivity develops.

Glukoza Hztm can interact with other intravenous agents and systemic medications.

Avoid: - Concurrent high‑dose insulin therapy without glucose monitoring. - Co‑administration with other hypertonic dextrose solutions.

Use with caution: - Loop diuretics that may alter electrolyte balance. - Catecholamine vasopressors that affect glucose metabolism. - Steroids or thiazide diuretics that raise blood glucose. - Total parenteral nutrition mixtures containing other carbohydrates.